文献速递重症综合管理与镇静镇痛

工业资助与非营利资助的重症医学研究:一项元流行病学概览

Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview.
PubMed 文献 · Intensive Care Med · 2018-08-27
一句话结论重症医学中工业资助的随机对照试验占少数,未见工业资助试验结果更有利或更少得出不利结论的证据。

该元流行病学研究系统汇编了重症医学领域评估各类干预措施并报告每项纳入随机对照试验资助来源的元分析,并检索了干预为药物或生物制品时元分析中资助信息不可用的原始随机对照试验文章,定性汇总资助来源。对二分类结局,分别计算有工业资助与无工业资助试验的汇总比值比,进而计算比值比的比值(ROR)及跨主题的汇总ROR(sROR)。共纳入67个主题、568项随机对照试验,其中88项由工业资助,另73项同时有工业与非营利资助;33个有二分类结局主题的sROR为1.10(95%CI 0.96-1.26,I2=1%)。工业资助试验中实验组干预结论不利的比例为21.3%,无工业资助试验为18.2%,差异未达统计学显著。

要点

  • 共纳入67个重症主题的568项随机对照试验,其中88项由工业资助,另73项同时有工业与非营利资助。
  • 33个有二分类结局主题的汇总比值比的比值(sROR)为1.10(95%CI 0.96-1.26,I2=1%),未达统计学显著。
  • 工业资助试验中实验组干预结论不利的比例为21.3%,无工业资助试验为18.2%,差异未达统计学显著。
  • 结论:重症医学中工业资助的随机对照试验占少数,未发现工业资助试验结果更有利或更少得出不利结论的证据。

适用人群与场景

  • 重症医学领域评估各类干预措施的随机对照试验,纳入系统汇编的元分析所涵盖的试验及干预为药物或生物制品时元分析中资助信息不可用的原始随机对照试验文章。

研究设计与关键结果

  • 研究类型为元流行病学概览,系统汇编重症医学领域评估各类干预措施并报告每项纳入随机对照试验资助来源的元分析,并在干预为药物或生物制品且元分析中资助信息不可用时检索原始随机对照试验文章。
  • 共纳入67个主题、568项随机对照试验,其中88项由工业资助,另73项同时有工业与非营利资助。
  • 对二分类结局分别计算有工业资助与无工业资助试验的汇总比值比,并计算比值比的比值(ROR)及跨主题的汇总ROR(sROR);ROR<1提示实验性干预在有工业资助试验中相对更有利。
  • 33个有二分类结局主题的sROR为1.10(95%CI 0.96-1.26,I2=1%)。
  • 工业资助试验中实验组干预结论不利的比例为21.3%,无工业资助试验为18.2%,差异未达统计学显著。

证据类型、等级与局限

  • 证据类型:元流行病学概览(系统汇编元分析及原始随机对照试验资助信息)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论为重症医学中工业资助的随机对照试验占少数,未发现工业资助试验结果更有利或更少得出不利结论的证据。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To study the landscape of funding in intensive care research and assess whether the reported outcomes of industry-funded randomized controlled trials (RCTs) are more favorable.

METHODS: We systematically assembled meta-analyses evaluating any type of intervention in the critical care setting and reporting the source of funding for each included RCT. Furthermore, when the intervention was a drug or biologic, we searched also the original RCT articles, when their funding information was unavailable in the meta-analysis. We then qualitatively summarized the sources of funding. For binary outcomes, separate summary odds ratios were calculated for trials with and without industry funding. We then calculated the ratio of odds ratios (RORs) and the summary ROR (sROR) across topics. ROR < 1 implies that the experimental intervention is relatively more favorable in trials with industry funding compared with trials without industry funding. For RCTs included in the ROR analysis, we also examined the conclusions of their abstract.

RESULTS: Across 67 topics with 568 RCTs, 88 were funded by industry and another 73 had both industry and non-profit funding. Across 33 topics with binary outcomes, the sROR was 1.10 [95% CI (0.96-1.26), I2 = 1%]. Conclusions were not significantly more commonly unfavorable for the experimental arm interventions in industry-funded trials (21.3%) compared with trials without industry funding (18.2%).

CONCLUSION: Industry-funded RCTs are the minority in intensive care. We found no evidence that industry-funded trials in intensive care yield more favorable results or are less likely to reach unfavorable conclusions.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Janiaud P, Cristea IA, Ioannidis JPA, et al. Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview. Intensive Care Med. 2018. PMID: 30151688. doi:10.1007/s00134-018-5325-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。